WHO’s mpox response aims to reduce disease burden, provides scope for developers
There is a huge opportunity for developers and manufacturers to advance novel prophylactic and treatment options, says GlobalData
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Emergent BioSolutions
US FDA approves Emergent’s smallpox vaccine for people at high risk of mpox
FDA approves Emergent's ACAM2000 smallpox vaccine for high-risk mpox patients, amid ongoing global health concerns and recent…
J&J gives notice to terminate Emergent manufacturing deal for COVID vaccine
The termination notice comes about a week after J&J had initially informed Emergent of its intent to end the pact based on the…
US CDC publishes guidelines on monkeypox vaccine
The vaccine was approved in the US in 2019 to prevent smallpox and monkeypox in high-risk adults aged 18 years and older
US gives charge of facility that botched COVID vaccine to J&J, stops AstraZeneca from using the…
AstraZeneca, whose vaccine has not been approved in the US, said it will work with President Joe Biden’s administration to find an…
J&J strikes deal with Emergent BioSolutions on coronavirus vaccine manufacturing
Under the deal, valued at about $135 million, Emergent said it would provide drug substance manufacturing services and was…